NO975730L - Metode for ökning av beskyttende immunresponser - Google Patents

Metode for ökning av beskyttende immunresponser

Info

Publication number
NO975730L
NO975730L NO975730A NO975730A NO975730L NO 975730 L NO975730 L NO 975730L NO 975730 A NO975730 A NO 975730A NO 975730 A NO975730 A NO 975730A NO 975730 L NO975730 L NO 975730L
Authority
NO
Norway
Prior art keywords
immune responses
methods
protective immune
polypeptides
enhance
Prior art date
Application number
NO975730A
Other languages
English (en)
Other versions
NO975730D0 (no
Inventor
Steven G Reed
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/607,509 external-priority patent/US5876735A/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO975730D0 publication Critical patent/NO975730D0/no
Publication of NO975730L publication Critical patent/NO975730L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Metoder for å fremkalle eller øke immunresponser overfor antigener, inkludert tumorantigener og/eller DNA-vaksiner presenteres. Fremgangsmåtene benytter polypeptider eller nukleinsyreblandinger som inneholder minst en biologisk aktiv del av en homolog av den eukaryote initieringsfaktor 4A fra Leishmania braziliensis eller Leishmania major, eller en variant av denne. Slike polypeptider og blandinger kan brukes for å øke eller fremkalle en pasients cellulære og/eller humorale immunresponser, f.eks innen metoder som benyttes for å behandle tumores.
NO975730A 1995-06-06 1997-12-05 Metode for ökning av beskyttende immunresponser NO975730L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48838695A 1995-06-06 1995-06-06
US08/607,509 US5876735A (en) 1994-04-22 1996-02-23 Methods for enhancement of protective immune responses
US08/634,642 US5879687A (en) 1994-04-22 1996-04-18 Methods for enhancement of protective immune responses
PCT/US1996/009141 WO1996039524A1 (en) 1995-06-06 1996-06-05 Methods for enhancement of protective immune responses

Publications (2)

Publication Number Publication Date
NO975730D0 NO975730D0 (no) 1997-12-05
NO975730L true NO975730L (no) 1998-02-05

Family

ID=27413802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975730A NO975730L (no) 1995-06-06 1997-12-05 Metode for ökning av beskyttende immunresponser

Country Status (11)

Country Link
US (1) US5879687A (no)
EP (1) EP0832236A1 (no)
JP (1) JP2001503014A (no)
KR (1) KR19990022654A (no)
CN (1) CN1194000A (no)
AU (1) AU5988096A (no)
BR (1) BR9608898A (no)
CA (1) CA2223421A1 (no)
NO (1) NO975730L (no)
NZ (1) NZ309659A (no)
WO (1) WO1996039524A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0686030T3 (da) * 1993-12-23 2001-06-25 Rmf Dictagene Sa Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US6607731B1 (en) 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6500437B1 (en) 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6638517B2 (en) 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US20060029653A1 (en) 1997-01-29 2006-02-09 Cronk Peter J Therapeutic delivery system
CZ298347B6 (cs) * 1998-02-05 2007-09-05 Glaxosmithkline Biologicals S.A. Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny
US20050158856A1 (en) * 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
FR2862313B1 (fr) * 2003-11-19 2006-02-24 Inst Rech Developpement Ird Nouveaux moyens pour la prevention des leishmanioses
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2007121184A2 (en) 2006-04-10 2007-10-25 The Infectious Disease Research Institute Inc. Compounds and methods for diagnosis and treatment of leishmaniasis
JP2010502310A (ja) 2006-08-30 2010-01-28 ディヴィッド・ウィリアム・スミス 押出成形された材料に単軸又は多軸方向の剛性を付与する方法及び同方法により得られる製品
CN102083853B (zh) 2008-07-03 2014-09-17 传染性疾病研究院 融合蛋白及其在利什曼病的诊断和治疗中的用途
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
US9545421B2 (en) 2010-05-04 2017-01-17 General Electric Company Nucleic acid delivery vehicle and uses thereof
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
CN111154807B (zh) * 2020-01-17 2023-03-24 山东农业大学 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法
DE102022131277A1 (de) 2022-11-25 2024-05-29 Schwäbische Hüttenwerke Automotive GmbH Pumpe-Motor-Einheit mit integrierter Kühlung einer Elektronikkomponente

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
US5543143A (en) * 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
WO1995029239A2 (en) * 1994-04-22 1995-11-02 Corixa Corporation Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production

Also Published As

Publication number Publication date
CA2223421A1 (en) 1996-12-12
NZ309659A (en) 2000-01-28
EP0832236A1 (en) 1998-04-01
WO1996039524A1 (en) 1996-12-12
KR19990022654A (ko) 1999-03-25
US5879687A (en) 1999-03-09
AU5988096A (en) 1996-12-24
MX9709737A (es) 1998-10-31
JP2001503014A (ja) 2001-03-06
CN1194000A (zh) 1998-09-23
NO975730D0 (no) 1997-12-05
BR9608898A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
NO975730L (no) Metode for ökning av beskyttende immunresponser
WO1999029341A3 (en) Methods for enhancement of protective immume responses employing leishmania polypeptides
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
HUP9901254A2 (hu) Nemdendrites szerkezetű gerincet alkotó peptid hordozó
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
IL144371A0 (en) Her-2/neu fusion proteins
CA2203991A1 (en) Methods and devices for immunizing a host to tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
ATE456378T1 (de) Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
ES500567A0 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
IT1262895B (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
HK51597A (en) Vaccines for human respiratory virus
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
BR0010155A (pt) Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
EP0110791A3 (en) Peptides containing an immunogenic site of the poliovirus, and dna's containing nucleotide fragments encoding for these peptides
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
PL288140A1 (en) Polypeptide, vaccine, expression vector, method of immunizing human organisms, method of obtaining polypeptide and method of obtaining such vaccine and expression vector
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2002072013A8 (en) Method of treating malignancies through induction of blood immune responses
EP0317622A4 (en) PREVENTION AND TREATMENT OF RETROVIRUS DISEASE.
EP1502602A3 (en) Methods for therapeutic vaccination
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application